One man's side effect is another man's therapeutic opportunity: Targeting Kv7 channels in smooth muscle disorders

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 19-27

  Jepps, T A ^a   Olesen, S P ^b   Greenwood, I A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

hypertension; ion channels; KCNQ; Kv7 channels; retigabine; smooth muscle; voltage gated potassium channels

Indexed keywords

ACRYLAMIDE DERIVATIVE; BENZAMIDE DERIVATIVE; CELECOXIB; DICLOFENAC; FLINDOKALNER; FLUPIRTINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ICA 27243; MEFENAMIC ACID; N (6 CHLOROPYRIDIN 3 YL) 3,4 DIFLUOROBENZAMIDE; N [1 (3 MORPHOLIN 4 YLPHENYL)ETHYL] 3 PHENYLACRYLAMIDE; PLACEBO; POTASSIUM CHANNEL KCNQ4; RETIGABINE; UNCLASSIFIED DRUG;

BLADDER INSTABILITY; BRAIN NERVE CELL; CHRONIC PAIN; CONSTIPATION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; EPILEPSY; HUMAN; HYPERTENSION; MUSCLE DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE; SMOOTH MUSCLE DISEASE; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE;

ANIMALS; ANTICONVULSANTS; CARBAMATES; CONSTIPATION; FEMALE; HUMANS; HYPERTENSION; KCNQ1 POTASSIUM CHANNEL; MEMBRANE POTENTIALS; MEMBRANE TRANSPORT MODULATORS; MUSCLE TONUS; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; MUSCULAR DISEASES; NEURONS; OBSTETRIC LABOR, PREMATURE; PHENYLENEDIAMINES; POTASSIUM CHANNELS, VOLTAGE-GATED; PREGNANCY; URINARY BLADDER DISEASES;

EID: 84872854264     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02133.x     Document Type: Review

References (78)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Anderson UA, Carson C, McCloskey KD, (2009). KCNQ currents and their contribution to resting membrane potential and the excitability of interstitial cells of Cajal from the guinea pig bladder. J Urol 182: 330-336.
3. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G, (1996). K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 384: 78-80.
4. Beisel KW, Nelson NC, Delimont DC, Fritzsch B, (2000). Longitudinal gradients of KCNQ4 expression in spiral ganglion and cochlear hair cells correlate with progressive hearing loss in DFNA2. Brain Res Mol Brain Res 82: 137-149.
5. Bentzen BH, Schmitt N, Calloe K, Dalby-Brown W, Grunnet M, Olesen SP, (2006). The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology 51: 1068-1077.
6. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, et al,. (1998). A potassium channel mutation in neonatal human epilepsy. Science 279: 403-406.
7. Blom SM, Schmitt N, Jensen HS, (2010). Differential effects of ICA-27243 on cloned Kv7 channels. Pharmacology 86: 174-181.
8. Brickel N, Gandhi P, Vanlandingham K, Hammond J, Derossett S, (2012). The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia 53: 606-612.
9. Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, et al,.; RESTORE 2 Study Group (2010). Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75: 1817-1824.
10. Brown DA, Adams PR, (1980). Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 283: 673-676.
11. Brueggemann LI, Moran CJ, Barakat JA, Yeh JZ, Cribbs LL, Byron KL, (2007). Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 292: H1352-H1363.
12. Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL, (2009). Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 76: 1053-1061.
13. Brueggemann LI, Mackie AR, Martin JL, Cribbs LL, Byron KL, (2011). Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits. Mol Pharmacol 79: 10-23.
14. Brueggemann LI, Kakad PP, Love RB, Solway J, Dowell ML, Cribbs LL, et al,. (2012). Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy. Am J Physiol Lung Cell Mol Physiol 302: L120-L132.
15. Chadha PS, Zunke F, Zhu HL, Davis AJ, Jepps TA, Olesen SP, et al,. (2012a). Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies impaired β-adrenoceptor-mediated relaxation of renal arteries in hypertension. Hypertension 59: 877-884.
16. Chadha PS, Zunke F, Davis AJ, Jepps TA, Linders JT, Schwake M, et al,. (2012b). Pharmacological dissection of Kv 7.1 channels in systemic and pulmonary arteries. Br J Pharmacol 166: 1377-1387.
17. Dailey JW, Cheong JH, Ko KH, Adams-Curtis LE, Jobe PC, (1995). Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci Lett 195: 77-80.
18. Du XN, Zhang X, Qi JL, An HL, Li JW, Wan YM, et al,. (2011). Characteristics and molecular basis of celecoxib modulation on Kv7 potassium channels. Br J Pharmacol 164: 1722-1737.
19. Fattore C, Perucca E, (2011). Novel medications for epilepsy. Drugs 71: 2151-2178.
20. French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, et al,.; RESTORE 1/Study 301 Investigators (2011). Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76: 1555-1563.
21. Gollasch M, (2012). Vasodilator signals from perivascular adipose tissue. Br J Pharmacol 165: 633-642.
22. Gollasch M, Dubrovska G, (2004). Paracrine role for periadventitial adipose tissue in the regulation of arterial tone. Trends Pharmacol Sci 25: 647-653.
23. Greenwood IA, Ohya S, (2009). New tricks for old dogs: KCNQ expression and role in smooth muscle. Br J Pharmacol 156: 1196-1203.
24. + channel opener for the treatment of epilepsy. Epilepsia 53: 412-424.
25. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, et al,. (2005). International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57: 473-508.
26. Harden CL, (2012). Ezogabine AKA retigabine: is more better? Trying to find the right dose from clinical trials. Epilepsy Curr 12: 27-28.
27. Herrmann WM, Kern U, Aigner M, (1987). On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 63 (Suppl. 3): 87-103.
28. Ipavec V, Martire M, Barrese V, Taglialatela M, Currò D, (2011). Kv7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus. Pharmacol Res 64: 397-409.
29. + channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol 297: G107-G115.
30. Jepps TA, Chadha PS, Davis AJ, Harhun MI, Cockerill GW, Olesen SP, et al,. (2011). Downregulation of Kv7.4 channel activity in primary and secondary hypertension. Circulation 124: 602-611.
31. Joshi S, Balan P, Gurney AM, (2006). Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 7: 31-40.
32. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM, (2009). KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther 329: 368-376.
33. + channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 97: 4333-4338.
34. Kubisch C, Schroeder BC, Friedrich T, Lütjohann B, El-Amraoui A, Marlin S, et al,. (1999). KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96: 437-446.
35. Kupferberg HJ, (1989). Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia 30 (Suppl. 1): S51-S56.
36. + channels. Mol Pharmacol 75: 272-280.
37. Large CH, Sokal DM, Nehlig A, Gunthorpe MJ, Sankar R, Crean CS, et al,. (2012). The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia 53: 425-436.
38. Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, Busch AE, et al,. (2000). Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J Biol Chem 275: 22395-22400.
39. McCallum LA, Greenwood IA, Tribe RM, (2009). Expression and function of Kv7 channels in murine myometrium throughout oestrous cycle. Pflugers Arch. 457: 1111-1120.
40. McCallum LA, Pierce SL, England SK, Greenwood IA, Tribe RM, (2011). The contribution of Kv7 channels to pregnant mouse and human myometrial contractility. J Cell Mol Med 15: 577-586.
41. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, et al,. (2008). Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325: 475-483.
42. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA, (2000). Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58: 253-262.
43. Mani BK, Brueggemann LI, Cribbs LL, Byron KL, (2011). Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br J Pharmacol 164: 237-249.
44. v7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol 157: 1241-1249.
45. Ng FL, Davis AJ, Jepps TA, Harhun MI, Yeung SY, Wan A, et al,. (2011). Expression and function of the K+ channel KCNQ genes in human arteries. Br J Pharmacol 162: 42-53.
46. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y, (2002). Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physical Gatrointest Liver Physiol 282: G277-G287.
47. Ohya S, Sergeant GP, Greenwood IA, Horowitz B, (2003). Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current. Circ Res 92: 1016-1023.
48. Padilla K, Wickenden AD, Gerlach AC, McCormack K, (2009). The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett 465: 138-142.
49. Rejdak K, Luszczki JJ, Błaszczyk B, Chwedorowicz R, Czuczwar SJ, (2012). Clinical utility of adjunctive retigabine in partial onset seizures in adults. Ther Clin Risk Manag 8: 7-14.
50. Rode F, Svalø J, Sheykhzade M, Rønn LC, (2010). Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol 638: 121-127.
51. Roeloffs R, Wickenden AD, Crean C, Werness S, McNaughton-Smith G, Stables J, et al,. (2008). In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4- difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models. J Pharmacol Exp Ther 326: 818-828.
52. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, et al,. (1996). D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23: 211-223.
53. + channels in neuronal cells. Eur J Pharmacol 336: 243-249.
54. Rundfeldt C, Netzer R, (2000). The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary cells transfected with human KCNQ2/3 subunits. Neurosci Lett 282: 73-76.
55. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, et al,. (1996). Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 384: 80-83.
56. + channel sensitivity to the anticonvulsant retigabine. J Neurosci 25: 5051-5060.
57. Schleifenbaum J, Köhn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, et al,. (2010). Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens 28: 1875-1882.
58. Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, Greger R, et al,. (2000a). A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature 403: 196-199.
59. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ, (2000b). KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 275: 24089-24095.
60. Selyanko AA, Hadley JK, Wood IC, Abogadie FC, Delmas P, Buckley NJ, et al,. (1999). Two types of K(+) channel subunit, Erg1 and KCNQ2/3, contribute to the M-like current in a mammalian neuronal cell. J Neurosci 19: 7742-7756.
61. Shah MM, Mistry M, Marsh SJ, Brown DA, Delmas P, (2002). Molecular correlates of the M-current in cultured rat hippocampal neurons. J Physiol 544: 29-37.
62. Søgaard R, Ljungstrøm T, Pedersen KA, Olesen SP, Jensen BS, (2001). KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol 280: C859-C866.
63. Soldovieri MV, Miceli F, Taglialatela M, (2011). Driving with no brakes: molecular pathophysiology of Kv7 potassium channels. Physiology (Bethesda) 26: 365-376.
64. + channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 172: 2054-2058.
65. Suh BC, Inoue T, Meyer T, Hille B, (2006). Rapid chemically induced changes of PtdIns(4,5)P2 gate KCNQ ion channels. Science 314: 1454-1457.
66. Svalø J, Hansen HH, Rønn LC, Sheykhzade M, Munro G, Rode F, (2011). Kv7 positive modulators reduce detrusor overactivity and increase bladder capacity in rats. Basic Clin Pharmacol Toxicol 110: 145-153.
67. Tatulian L, Delmas P, Abogadie FC, Brown DA, (2001). Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21: 5535-5545.
68. Tober C, Rostock A, Rundfeldt C, Bartsch R, (1996). D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303: 163-169.
69. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, et al,. (1998). KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282: 1890-1893.
70. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, et al,. (1996). Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 12: 17-23.
71. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK, (2000). Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58: 591-600.
72. Wickenden AD, Krajewski JL, London B, Wagoner PK, Wilson WA, Clark S, et al,. (2008). N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol 73: 977-986.
73. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H, (2005). The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67: 1009-1017.
74. Xiong Q, Gao Z, Wang W, Li M, (2008). Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci 29: 99-107.
75. Yeung S, Schwake M, Pucovský V, Greenwood IA, (2008). Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. Br J Pharmacol 155: 62-72.
76. Yeung SY, Greenwood IA, (2005). Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol 146: 585-595.
77. Yeung SY, Pucovský V, Moffatt JD, Saldanha L, Schwake M, Ohya S, et al,. (2007). Molecular expression and pharmacological identification of a role for Kv7 channels in murine vascular reactivity. Br J Pharmacol 151: 758-770.
78. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, et al,. (2010). Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol 588: 3277-3293.